The estimated Net Worth of Huw M. Nash is at least $4.08 Million dollars as of 20 May 2024. Huw Nash owns over 50,000 units of Stoke Therapeutics stock worth over $737,000 and over the last 5 years he sold STOK stock worth over $2,474,889. In addition, he makes $869,855 as Chief Operating Officer and Chief Business Officer at Stoke Therapeutics.
Sign up
Huw Nash STOK stock SEC Form 4 insiders trading
Huw has made over 27 trades of the Stoke Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 2,500 units of STOK stock worth $32,775 on 2 July 2024.
The largest trade he's ever made was selling 61,329 units of Stoke Therapeutics stock on 1 April 2024 worth over $811,383. On average, Huw trades about 11,988 units every 47 days since 2020. As of 20 May 2024 he still owns at least 50,000 units of Stoke Therapeutics stock.
You can see the complete history of Huw Nash stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Huw Nash biography
Dr. Huw M. Nash is Chief Operating Officer, Chief Business Officer of the Company. Dr. Nash also served as an Entrepreneur-in-Residence at Apple Tree Partners, a venture capital firm. While at Apple Tree Partners, Dr. Nash was part of the founding group of entrepreneurs who worked on the original platform technology for Aileron Therapeutics, Inc., a biopharmaceutical company. Dr. Nash also served as Vice President of Corporate Development at Aileron Therapeutics, Inc. from 2005 to 2013. Prior to joining Aileron Therapeutics, Inc., Dr. Nash was a founding scientist of NeoGenesis Pharmaceuticals, Inc., a drug discovery company, where he served as Vice President of External Collaborations from 1997 to 2005 until its acquisition by Schering-Plough Corp. Dr. Nash holds a B.A. in Biochemical Sciences from Harvard College and a Ph.D. in Organic Chemistry from Harvard University.
What is the salary of Huw Nash?
As the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics, the total compensation of Huw Nash at Stoke Therapeutics is $869,855. There are 3 executives at Stoke Therapeutics getting paid more, with Stephen Tulipano having the highest compensation of $1,176,400.
How old is Huw Nash?
Huw Nash is 53, he's been the Chief Operating Officer and Chief Business Officer of Stoke Therapeutics since 2017. There are 16 older and 5 younger executives at Stoke Therapeutics. The oldest executive at Stoke Therapeutics, Inc. is Dr. Edward M. Kaye M.D., Ph.D., 72, who is the CEO & Director.
What's Huw Nash's mailing address?
Huw's mailing address filed with the SEC is C/O STOKE THERAPEUTICS, INC., 45 WIGGINS AVENUE, BEDFORD, MA, 01730.
Insiders trading at Stoke Therapeutics
Over the last 5 years, insiders at Stoke Therapeutics have traded over $49,612,288 worth of Stoke Therapeutics stock and bought 4,288,550 units worth $94,976,062 . The most active insiders traders include Group, Llc Green Jeremy Red..., Investments, Lpwong Roderic..., and Trust Blue Horizon Enterpri.... On average, Stoke Therapeutics executives and independent directors trade stock every 23 days with the average trade being worth of $1,639,987. The most recent stock trade was executed by Barry Ticho on 3 September 2024, trading 10,000 units of STOK stock currently worth $6,000.
What does Stoke Therapeutics do?
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
What does Stoke Therapeutics's logo look like?
Complete history of Huw Nash stock trades at Stoke Therapeutics
Stoke Therapeutics executives and stock owners
Stoke Therapeutics executives and other stock owners filed with the SEC include:
-
Stephen Tulipano,
Chief Financial Officer -
Dr. Edward M. Kaye,
CEO & Director -
Dr. Edward M. Kaye M.D., Ph.D.,
CEO & Director -
Huw Nash,
Chief Operating Officer, Chief Business Officer -
Barry Ticho,
Chief Medical Officer -
Edward Kaye,
Chief Executive Officer, Director -
Dr. Barry S. Ticho FACC, M.D., Ph.D.,
Chief Medical Officer -
Stephen J. Tulipano CPA, CPA, MBA,
Chief Financial Officer -
Seth Harrison,
Independent Chairman of the Board -
Jennifer Burstein,
Independent Director -
Adrian Krainer,
Independent Director -
Arthur Tzianabos,
Independent Director -
Arthur Levin,
Independent Director -
Dr. Adrian R. Krainer Ph.D.,
Co-Founder, Independent Director & Member of Scientific Advisory Board -
Garry Menzel,
Independent Director -
Julie Smith,
Independent Director -
Gene Liau,
Executive Vice President, Head of Research and Preclinical Development -
Dawn Kalmar,
Chief Communications Officer -
Jonathan Allan J.D.,
Deputy Gen. Counsel -
Dr. Gene Liau,
Chief Scientific Officer -
Dr. Huw M. Nash Ph.D.,
COO & Chief Bus. Officer -
Nancy M. Wyant,
VP & Head of Clinical Operations -
Shamim Ruff,
Chief Regulatory Officer -
Joan Wood,
Head of HR -
Isabel Aznarez Ph.D.,
Co-Founder, VP & Head of Biology -
Group, Llc Green Jeremy Red...,
-
Samuel W. Hall,
Director -
Life Science Ventures, L.P....,
-
Investments, Lpwong Roderic...,
-
Robin A. Walker,
Chief Legal Officer, CCO & Sec -
Jonathan Allan,
GENERAL COUNSEL & CORP SEC -
Trust Blue Horizon Enterpri...,
-
Thomas Leggett,
Chief Financial Officer -
Ian F Smith,